Company intelligence / Profile preview
ImmuneSensor Therapeutics
Dallas, Texas, USAimmunesensor.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
ImmuneSensor has completed a Phase 1 trial of its STING agonist IMSA101 in solid tumors and established the recommended Phase 2 dose. The company initiated a first-in-human Phase 1 trial of its oral cGAS inhibitor IMSB301 in healthy volunteers in late 2024. Preclinical data show potent inhibition of the cGAS enzyme with strong suppression of cytokine production and rescue from disease phenotype in animal models. Orphan Drug and Rare Pediatric Disease designations have been granted by the FDA for AGS.[5] Safety/pharmacokinetic data from the ongoing trials are expected by end of year.
- Therapeutic areas
- OncologyImmunologyNephrology
- Modalities
- Small molecules (cGAS inhibitors and STING agonists)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Collaborates with University of Texas Southwestern Medical Center for foundational research/IP licensingReceived $16M grant from Cancer Prevention & Research Institute of Texas for cancer immunotherapy developmentEngages contract research organizations and global clinical partners as part of R&D operations
Beyond the preview
Go deeper on ImmuneSensor Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmuneSensor Therapeutics.